Real World Multi-Omics Not Lost in Clinical Translation
|
Robert P. Loewe GeneSurge GmbH, Germany |
Abstract
Multi-Omics gives new possibilities in comprehensive biomarker testing in real world patients. While NGS seems to be commonplace in a vast number of predominantly cancer patients, it scope is mainly relatively narrow. Giving examples of patients and their therapy adjustments via multi-omics analysis, a broader approach is presented that utilises mainly whole exome sequencing and full transcriptomic RNA-Seq. Comparing data from liquid biopsies with tissue derived and also illustrating future steps how e.g., epigenetic data can enrich data sets, new approaches are presented that will enable not only off-label use of single drugs in individual patients but also allow faster and more efficient drug repurposing.
| Back to GQ2023 session page | Back to GQ2023 overview page |
